The C-terminal extension of human telomerase reverse transcriptase is necessary for high affinity binding to telomeric DNA  by Tomlinson, Christopher G. et al.
lable at ScienceDirect
Biochimie 128-129 (2016) 114e121Contents lists avaiBiochimie
journal homepage: www.elsevier .com/locate/b iochiResearch paperThe C-terminal extension of human telomerase reverse transcriptase
is necessary for high afﬁnity binding to telomeric DNA
Christopher G. Tomlinson a, 1, Jessica K. Holien b, 1, Jordan A.T. Mathias a, 1,
Michael W. Parker b, c, Tracy M. Bryan a, *
a Children's Medical Research Institute, University of Sydney, Westmead, NSW, 2145, Australia
b ACRF Rational Drug Discovery Centre, St Vincent's Institute of Medical Research, Fitzroy, Victoria, 3065, Australia
c Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria,
3010, Australiaa r t i c l e i n f o
Article history:
Received 18 May 2016
Accepted 20 July 2016
Available online 22 July 2016
Keywords:
Cancer
Telomerase
Short telomere syndromes
Biochemistry
Molecular modellingAbbreviations: ALT, alternative lengthening of t
reverse transcriptase; TR, telomerase RNA; DKC,
essential N-terminus; TRBD, telomerase RNA bin
transcriptase; CTE, C-terminal extension.
* Corresponding author.
E-mail address: tbryan@cmri.org.au (T.M. Bryan).
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.biochi.2016.07.010
0300-9084/© 2016 The Authors. Published by Elseviera b s t r a c t
The ribonucleoprotein enzyme telomerase maintains telomeres and is essential for cellular immortality
in most cancers. Insight into the telomerase mechanism can be gained from short telomere syndromes,
in which mutation of telomerase components manifests in telomere dysfunction. We carried out detailed
kinetic analyses and molecular modelling of a disease-associated mutant in the C-terminal extension of
the reverse transcriptase subunit of human telomerase. The kinetic analyses revealed that the mutation
substantially impacts the afﬁnity of telomerase for telomeric DNA, but the magnitude of this impact
varies for primers with different 30 ends. Molecular dynamics simulations corroborate this ﬁnding,
revealing that the mutation results in greater movement of a nearby loop, impacting the DNA-RNA helix
differentially with different DNA primers. Thus, the data indicate that this region is the location of one of
the enzyme conformational changes responsible for the long-standing observation that off-rates of
telomerase vary with telomeric 30 end sequence. Our data provide a molecular basis for a disease-
associated telomerase mutation, and the ﬁrst direct evidence for a role of the C-terminal extension in
DNA binding afﬁnity, a function analogous to the “thumb” domain of retroviral reverse transcriptases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ends of human chromosomes (telomeres) consist of the
repeating DNA sequence 50- [TTAGGG]-30 and telomere-associated
proteins [1,2]. These structures protect the ends of chromosomes
from being mistakenly recognised as DNA double strand breaks.
Telomeres in normal cells shorten with each cell division; eventu-
ally a critical threshold is reached that signals the cell to stop
dividing, a process known as cellular senescence [3].
Cancer cells are able to counteract telomere shortening by one of
two distinct mechanisms: through the activation of the ribonu-
cleoprotein telomerase [4,5] or via the alternative lengthening ofelomeres; TERT, telomerase
dyskerin; TEN, telomerase
ding domain; RT, reverse
B.V. This is an open access article utelomeres (ALT) pathway [6]. Approximately 90% of all human
cancers contain high levels of telomerase, allowing them to pro-
liferate indeﬁnitely. This is in contrast to normal cells, which have
very low or undetectable telomerase levels. Telomerase is therefore
a promising target for the discovery and development of non-toxic
cancer therapeutics.
The three primary components of the human telomerase ribo-
nucleoprotein enzyme are the catalytic subunit (telomerase reverse
transcriptase, hTERT) [7,8], an RNA component containing the
template (hTR) [9], and the protein dyskerin (DKC) [10,11]. Deﬁ-
ciency of telomerase activity in stem cells, resulting frommutations
in genes encoding telomerase or telomerase-associated proteins,
can manifest in ‘short telomere syndromes’ such as dyskeratosis
congenita, idiopathic pulmonary ﬁbrosis and aplastic anaemia
[12e14]. These naturally-occurring disease mutations can be a
source of insight into telomerase mechanism [15e17].
The catalytic subunit of human telomerase contains four
conserved structural domains: the telomerase essential N terminus
(TEN), the telomerase RNA binding domain (TRBD), the reverse
transcriptase (RT) domain and the C-terminal extension (CTE)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C.G. Tomlinson et al. / Biochimie 128-129 (2016) 114e121 115(Fig. 1A). Crystal structures of hTERT remain elusive; however, a
human TERT homology model created by threaded sequence
alignment with close structural analogues [17] provides a useful
guide to the architecture of human TERT (Fig. 1B). The RT domain
contains seven conserved motifs shared with conventional RTs and
a catalytic triad of universally conserved aspartate residues;
mutating any of these three residues abolishes telomerase activity
[7]. This indicates that telomerase shares a catalytic mechanism in
commonwith other reverse transcriptases, whereby metal ions are
bound and stabilise developing negative charge during nucleotide
addition. However, to enable repetitive copying of a short 6 base
region of template sequence, telomerase has evolved a unique
mechanism for handling its RNA template and DNA substrate,
involving translocation of the template and repositioning of the 30
end of the DNA in the active site [18]. Protein-DNA interactions play
a substantial role in this process; the TEN domain provides high-
afﬁnity DNA binding and stabilises the 30 end of the DNA in the
active site, and amino acids in the RT domain are also important for
DNA afﬁnity [17,19e25]. In addition, telomeric DNA primers with
different 30 ends (Fig. 1C) vary signiﬁcantly in rates of dissociation
from telomerase [26]. Our kinetic and thermodynamic analyses of
telomerase revealed that differences in dissociation rates between
primers with different 30 ends were independent of DNA afﬁnities,
demonstrating that initial binding of telomerase to telomeric DNA
occurs via a two-step mechanism that likely involves enzyme
conformational changes that differ at all six positions of the tem-
plate [17].
The function of the CTE of hTERT is not well characterised;
however, there is some evidence for roles in in vivo and in vitro
telomerase activity, low afﬁnity DNA binding, and processivity
[27,28]. To explore the role of the CTE, we measured the thermo-
dynamic and kinetic DNA binding parameters of a disease-
associated variant telomerase (C1015R) that was identiﬁed in a
patient suffering from therapy-refractory aplastic anaemia [29].
C1015 is well conserved and located in the E-1motif of the CTE, that
was shown to be essential for in vitro and in vivo telomerase ac-
tivity, although its function is unknown (Fig. 1A) [28]. In our ho-
mology model, C1015 is located on a helix close to the RT domain
(Fig. 1B, yellow). The C1015R mutation is known to impact telo-
merase activity, as measured by a PCR-based “TRAP” assay [29], but
the mechanistic basis of this defect is unknown. Here we show that
C1015R substantially impacts the afﬁnity of telomerase for DNAFig. 1. Location of the hTERT amino acid mutation C1015R, and telomeric DNA alignment
locations of the telomerase essential N-terminal (TEN) domain, RNA binding domain (RBD),
mutation C1015R in the C-terminal extension is highlighted; coloured boxes indicate con
Highlighted are helix 4 (yellow), C1015R (yellow sticks), a loop of amino acids (957e965; gr
triad of aspartates (D712, D868 and D869, atom coloured sticks). (C) Alignment of permutadifferentially with different primers, providing the ﬁrst direct evi-
dence for a role of the CTE in DNA binding afﬁnity. This is supported
by computational modelling of C1015Rwithin our homologymodel
of hTERT; molecular dynamics simulations suggest that this mu-
tation results in increased movement in a nearby region of hTERT.
We have therefore identiﬁed a possible region of enzyme confor-
mational change that is important for the differential binding of
different DNA primers by hTERT.
2. Materials and methods
2.1. Plasmids and oligonucleotides
The hTERT gene [30] under a cytomegalovirus (CMV) promoter
was cloned into plasmid pAPEX-3P [22,31]. The hTR gene under a
U3 promoter [32] and dyskerin (OriGene Technologies) under a
CMV promoter were cloned into a single plasmid in vector pAPEX-3
[22]. The C1015R hTERT mutation was constructed with the Stra-
tagene Quikchange II-E Site-Directed Mutagenesis kit according to
the manufacturer's instructions. Templating primers 50- GTA-
CAGGTTTCACGCACGTGTGCTGCAGCTCC-30 and 50- GGAGCTGCAG-
CACACGTGCGTGAAACCTGTAC-30 were used to insert the C1015R
mutation. All oligonucleotides (Table 1) were purchased from
Sigma-Aldrich.
2.2. Cell culture, transfection and immunopuriﬁcation of telomerase
Cell culture, transfection and immunopuriﬁcation of telomerase
was performed as described elsewhere [17].
2.3. Telomerase activity assays
2.3.1. Modiﬁed telospot assay
Primer KM was determined using the medium-throughput
‘Telospot’ direct telomerase activity assay [33] with minor modiﬁ-
cations. All reaction mixtures had a ﬁnal volume of 50 mL, were set
up in a 96 well plate (Bioplastics) and performed at 37 C. Bio-
tinylated DNA in the concentration range 0e320 nMwas incubated
in human telomerase buffer (20 mM HEPES-KOH, 2 mM MgCl2,
50 mM KCl, 5 mM DDT, 1 mM spermidine, 1% Triton X-100 and 10%
glycerol) together with 5 fmol of immunopuriﬁed human C1015R
telomerase. The telomerase-DNA complex was formed at 37 C forwith telomerase. (A) Linear representation of the domain structure of hTERT, showing
reverse transcriptase (RT) domain and C-terminal extension (CTE). The position of the
served sequence motifs. (B) Homology model of hTERT (without the TEN domain).
een) that separates C1015R from the DNA, RNA (blue), DNA (magenta) and the catalytic
ted 18 nt human telomeric DNA primers with the telomerase RNA template.
Table 1
Oligonucleotides used in this study.
Name Sequence
DNA-1 Biotin-TTAGGGTTAGGGTTAGGG
DNA-2 Biotin-TAGGGTTAGGGTTAGGGT
DNA-3 Biotin-AGGGTTAGGGTTAGGGTT
DNA-4 Biotin-GGGTTAGGGTTAGGGTTA
DNA-5 Biotin-GGTTAGGGTTAGGGTTAG
DNA-6 Biotin-GTTAGGGTTAGGGTTAGG
(GTTAGG)4 Biotin-GTTAGGGTTAGGGTTAGGGTTAGG
All sequences are listed 50e30 .
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dGTP, dATP and dTTP (each to a ﬁnal concentration of 10 mM). The
extension reaction was allowed to proceed for 20 min and stopped
by the addition of 50 mL formamide, heating at 90 C for 10 min
then ice for 5 min; 50 mL of each sample was then loaded onto XL
membrane (GE Healthcare Life Sciences) via a vacuum equipped
dot blot. The membrane was given 1 h to air dry, before the DNA
was cross-linked to the membrane using Stratalinker® UV cross-
linker. The membrane was hybridised at 65 C for 30 min in Church
buffer (1% BSA, 1 mM EDTA (pH 7.5), 500 mMNaHPO4 (pH 7.2), 65%
glycerol). The membrane was incubated with 32P-labelled Tel800
probe [34](10 million cpm) for >12 h with rotation. The membrane
was washed twice in 2  SSC (300 mM NaCl, 30 mM Tri-sodium
citrate, pH 7.0) for 15 min at room temperature, followed by
2 SSC for 30min at 60 C, with a ﬁnal wash in 0.1 SSC for 15min
at room temperature. The membrane was dried, exposed to a
phosphorimager screen, scanned with a Typhoon 9410 Worksta-
tion and quantiﬁed with ImageQuant software.
2.3.2. Direct processive activity assay
The direct activity assay was performed as described previously
[17] with the following modiﬁcations: a biotinylated DNA concen-
tration of 40 nM was used to deﬁne the total processive activity of
DNA-3, -4 and -5, and 80 nM was used with DNA-1, -2 and -6.
Processivity, deﬁned as the number of repeats at which half the
product molecules have dissociated from enzyme, was calculated
as described previously [35].
2.4. Telomerase DNA binding assays
Telomerase DNA binding assays were carried out as previously
described [17]. Biotinylated DNA concentrations in the range of
0e800 nM for DNA-1, -2, -3 and -6 and 0e1600 nM for DNA-4 and
-5 were required to form telomerase-DNA complexes with immu-
nopuriﬁed C1015R telomerase.
2.5. Dissociation rate assays
Dissociation rate assayswere carried out as previously described
[17] with the following modiﬁcations: Biotinylated DNA concen-
trations of 400, 600, 400 and 120 nM were required to form
telomerase-DNA complexes with immunopuriﬁed C1015R telo-
merase and DNA-1, -2, -4, and -6 respectively.
2.6. Molecular modelling
2.6.1. Model creation
A human TERT model was created as described elsewhere [17].
The DNA-RNA hairpin was replaced in Coot version 0.7 [36] with
the relevant human sequences. Thus for DNA-2 the RNA sequence
was 50-AACCCUAACUGA-30, which matched the DNA sequence
50eTTAGGGTTAGGGTe30, and for DNA-6, the RNA sequence was 50-CCUAACUGAGAA-30 with the corresponding DNA sequence 50-
TTAGGGTTAGG-3'. The residue C1015 was replaced with arginine in
Sybyl-X 2.1.1 (Certara L.P.) and each of the four models were then
minimised under the Tripos forceﬁeld for 10,000 iterations.
2.6.2. Molecular dynamics simulations
The molecular dynamics program NAMD [37] was used to
minimise the TERT models on a TELSA K20 GPUmachine (NVIDIA).
Four alternate models were used: WT TERT with DNA-6, TERT
C1015R with DNA-6, WT TERT with DNA-2, and TERT C1015R with
DNA-2. Each model was initially solvated with TIP3P water using
the Solvate plugin within VMD version 1.9 [38] with the rotate to
minimise volume selected, the boundary reduced to 1.8 and the box
padding increased to 20 Å in all directions. Charges were neutral-
ised with NaCl using the autoionise plugin within VMD version 1.9.
Each structure was then minimised and equalised for 1 ns under
the CHARMM27 all-atom force ﬁeld at 298 K. Langevin dynamics
were used with group pressure and langevin piston turned on.
Trajectory snapshots were collected every picosecond. A produc-
tion run was then completed four times for each alternate simu-
lation (i.e. 16 simulations in total) on this minimised structure for
10 ns using the same conditions as described above. A longer
simulation was also conducted of 100 ns, giving a total simulation
time of 140 ns for each model. Convergence was monitored by
plotting Root Mean Square Deviation (RMSD) as a function of the
entire simulation time. The ﬁrst 2 ns of the production runs was
calculated to be the equilibration stage, thus analyses were carried
out on the ﬁnal 8 ns of each production run. At the completion of
the simulations, the average RMSD was calculated for each residue
(centred on the alpha carbon backbone) over all frames of the
trajectory. The average of the four production runs were then
calculated and plotted with GraphPad Prism 6. The Hbond plugin of
VMDwas used to calculate the hydrogen bonds between the amino
acids and the DNA-RNA hybrid. Criteria for the formation of
hydrogen bonds were that the distance between hydrogen donor
(D) and hydrogen acceptor (A) atoms was less than the cut-off
distance of 3.2 Å and the angle D-H-A was less than the cut-off
angle of 42. The average occupancy of the hydrogen bonds was
calculated as a ratio between the number of the trajectory frames
containing the hydrogen bond of interest, and the total number of
frames.
3. Results and discussion
3.1. Disease associated variant C1015R has reduced telomerase
activity
To determine the primer concentrations yielding maximal ac-
tivity for each of the six permutations of a human telomeric 18 nt
DNA primer with C1015R telomerase (Fig. 2A, Table 1), primer KM
(the primer concentration at which half-maximal enzyme activity
is observed) was quantiﬁed. Activity was measured using immu-
nopuriﬁed telomerase overexpressed in 293T cells, and a direct (i.e.
non-PCR) “Telospot assay” [33] involving incorporation of nucleo-
tides and detection of reaction products with a 32P end-labelled
primer complementary to the telomeric DNA repeat (Fig. 2B). Ac-
tivity was measured across a range of DNA concentrations, and the
resulting curves ﬁt to a Michaelis-Menten equation to yield KM.
Primer KM was 5- to 15-fold higher than wild-type for all primers
except DNA-3 (Fig. 2C).
To quantify the effect of the C1015R mutation on telomerase
activity, we measured total processive activity using each of the six
DNAs at saturating DNA concentration, as determined by quantiﬁ-
cation of KM. Enzyme concentration was normalised by quantifying
the telomerase RNA component hTR (by northern blot) and the
Fig. 2. Disease-associated hTERT variant C1015R has reduced telomerase activity. (A) Alignment of permutated 18 nt human telomeric DNA primers with the telomerase RNA
template. (B) Example of a modiﬁed Telospot assay used to determine primer KM. Total activity is measured at varying primer concentration. (C) Primer KM for each of the six
permutations of the 18 nt DNA primer with both wild-type (black bars) and C1015R (grey bars) telomerase (wild-type data was taken from Ref. [17]). (D) Direct processive activity
assay of wild-type and C1015R telomerase extending each of the six permutations of the 18 nt DNA primer. LC: labelled 12 nt oligonucleotide as a recovery and loading control. A
DNA concentration of 40 nM was used for all primers with WT telomerase and DNA-3, -4 and -5 with C1015R telomerase; 80 nM was used for DNA-1, -2 and -6 with C1015R
telomerase. (E) Activity of wild-type (black bars) and C1015R (grey bars) telomerase relative to wild-type extension of DNA-3. All experiments were carried out in triplicate and
error bars denote standard error of the mean.
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blot) (Fig. S1A, B). Telomerase extension reactions containing
immunopuriﬁed telomerase and the respective DNA (Fig. 2D) were
initiated by the addition of radiolabelled nucleotides and stopped
at 20 min, which is within the linear range for wild-type and
C1015R telomerase, as shown in the time course reactions depicted
in Fig. S1C, D. Telomerase activity (i.e. total radiolabelled nucleotide
incorporated into product) was 3- to 5-fold lower for C1015R than
wild-type telomerase with all six telomeric primers (Fig. 2D, E).
Additionally, the C1015R mutation caused a modest processivity
defect (Table S1).
3.2. C1015R telomerase shows defects in DNA binding afﬁnity and
has faster DNA dissociation rates
To determine the mechanistic basis for this telomerase activity
defect, we carried out a detailed analysis of the DNA-binding
properties of C1015R telomerase, to detect any differences in the
two-step DNA binding mechanism we have previously describedfor wild-type telomerase [17].
To measure primer afﬁnity (KD) directly we used a pulldown
assay that we developed for Tetrahymena telomerase [39] and
adapted for use with human telomerase [17]. Biotinylated 18 nt
telomeric primers at varying concentrations were incubated with
immunopuriﬁed C1015R human telomerase before being removed
with NeutrAvidin beads; the amount of telomerase remaining in
the supernatant was quantiﬁed by probing dotblots for hTR. An
example of this assay with wild-type or C1015R telomerase and
DNA-1 is shown in Fig. 3B. Plots of the amount of C1015R telome-
rase bound vs DNA concentration, used to determine KD for each of
the six DNAs, are shown in Fig. S2A. C1015R telomerase displayed a
substantial increase in KD for each of the six primers when
compared to wild-type telomerase (Fig. 3C). Of interest, DNAs 1
through 5 displayed a 20- to 80-fold higher KD than wild-type,
whereas the defect with DNA-6was amore subtle 4-fold difference.
To measure C1015R telomerase-DNA dissociation rates (koff), the
primer of interest was incubated with immunopuriﬁed C1015R
telomerase to pre-form the telomerase-DNA complex, after which a
Fig. 3. C1015R telomerase shows defects in DNA binding afﬁnity and has faster DNA dissociation rates. (A) Alignment of permutated 18 nt human telomeric DNA primers with
the telomerase RNA template. (B) Primer binding assay used to determine DNA binding afﬁnity (KD) for wild-type and C1015R telomerase. As the concentration of DNA-1 was
increased, decreasing amounts of telomerase (measured by dotblot probed against hTR) remained in the supernatant after depletion of the DNA. (C) Plot of wild-type primer KD
(black bars) versus C1015R primer KD (grey bars) (wild-type data taken from Ref. [17]). (D) Measurement of DNA dissociation rate (koff) for wild-type and C1015R telomerase. The
primer of interest (shown here, DNA-6, 18 nt) was pre-bound to wild-type or C1015R telomerase. An excess of competing primer ((GTTAGG)4, 24 nt) was then added. Aliquots were
removed over time and primers remaining bound to telomerase were labelled with [a-32P]-dGTP. Control: DNA-6 and a 100-fold excess of (GTTAGG)4 incubated with C1015R
telomerase for 30 min then labelled with [a-32P]-dGTP. LC: labelled 12 nt oligonucleotide as a recovery and loading control. (E) Plot of wild-type koff (black bars) versus C1015R koff
(grey bars) (wild-type data taken from Ref. [17]). Note that the off-rate of wild-type telomerase from DNA-1 is not measurable at room temperature [17,26]; the half-life is >24 h, so
the koff in the graph (0.00048 min1) represents an upper limit. All experiments were carried out in triplicate and error bars denote standard error of the mean.
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Aliquots were removed over time and any primer which remained
associated with telomerase was labelled with the appropriate mix
of dNTPs. Examples with DNA-6 are shown in Fig. 3D. Off-rates
were determined by plotting the dissociation of the primer of in-
terest over time (Fig. S2B). Offerates were signiﬁcantly faster for
complexes formed between C1015R telomerase and DNA-1, -2 and
-6 than those with wild-type telomerase (Fig. 3E). It was not
possible to measure the off-rates for C1015R telomerase with DNA-
3 and -5 since we observed substrate inhibition of telomerase with
these primers at the DNA concentrations required for mutant
telomerase to be fully bound.
We previously showed that wild-type human telomerase binds
telomeric DNA via a two-step mechanism that involves enzyme
conformational change [17]. This conclusion, depicted in Fig. 4A,
was based on signiﬁcant differences in the off-rate for different
primers that were not reﬂected in the KD. When comparing the fold
difference in KD and koff betweenwild-type and C1015R telomerase
(Fig. 4B), we observed large differences in binding afﬁnities (KD)
that were not reﬂected in large differences in dissociation rates
(koff) for DNA-1, -2 and -4. For the binding afﬁnity to besubstantially weaker without the off-rate being proportionally
faster, there must be a decrease in either the DNA on-rate (kon) or
the rate of enzyme conformational change upon DNA binding (kF)
(Fig. 4C). The telomerase-DNA complex was pre-formed before
addition of competitor DNA, so changes in on-rate would not be
measured in the determination of the off-rate. Therefore, the data
suggest that the C1015R mutation impacts enzyme conformational
change upon binding of DNA-1, -2 and -4. In contrast, the fold
differences in binding afﬁnity and off-rate between wild-type and
C1015R telomerase with DNA-6 are equivalent; therefore, the
C1015R mutation does not appear to impact enzyme conforma-
tional change when binding DNA-6.
3.3. Molecular modelling suggests that C1015R causes a signiﬁcant
shift in a loop of hTERT
The RT domain is relatively well conserved, with our previously
published hTERT model bearing close resemblance to the crystal
structure of TERT from Tribolium castaneum (Fig. S3). Cysteine 1015
is located on helix 4 of the RT domain model. According to the
model, this residue does not directly interact with DNA; it is
Fig. 4. C1015R telomerase affects the rate of conformational change associated with the binding of telomeric DNA. (A) Formation of telomerase-DNA complexes via a one-step
rigid-body mechanism (top, KD, dissociation constant; koff, off-rate constant; kon, on-rate constant), or via two-step induced-ﬁt mechanism requiring conformational change
(bottom, kU, rate of unfolding; kF, rate of folding). Telomerase is represented by a black circle and telomeric DNA by a grey rectangle. (B) Plot showing fold difference in KD and koff for
C1015R compared to wild-type telomerase. (C) Equation describing formation of telomerase-DNA complexes via a two-step mechanism requiring conformational change. Red
arrows depict large change in KD and smaller change in koff as a result of the C1015R mutation. Blue arrow represents a putative alteration in the rate of enzyme conformational
change to rationalise the changes in KD and koff.
C.G. Tomlinson et al. / Biochimie 128-129 (2016) 114e121 119approximately 8 Å away, separated by an adjacent loop region of
amino acids 957-SLTFNRGFK-965 (Fig. 1B and 5A, green). The mu-
tation from cysteine to arginine, which has a larger side-chain, puts
this amino acid closer to the DNA (approximately 4.5 Å) (Fig. 5A).
We modelled DNA-2 and DNA-6 into the DNA binding groove
and conducted molecular dynamics simulations to explore the
differences in enzyme movement after DNA binding had reached
equilibrium. Very quickly in the simulation time, we could see
distinct differences between the C1015R and wild-type telomerase
models. Namely, the loop region (957-SLTFNRGFK-965), which
previously separated residue 1015 from the DNA, moves very close
to the DNA in the C1015R model. Tracking the movement of indi-
vidual amino acid residues over the simulations shows that this
loop region moves signiﬁcantly more (approximately 5 Å) on
average over the course of the simulations for the C1015R telo-
merase models when compared to the wild-type models (Fig. 5B).
Visual analysis shows this steric shift may be due to the larger
arginine residue. Thus it is possible that the arginine in this position
necessitates greater movement of the loop in order for it to be
accommodated between helix 4 and the DNA.
This analysis also showed some differences in simulated enzyme
movement when telomerase was bound to different DNA primers.
The greatest movement in the loop regionwhen C1015Rwas bound
to DNA-6 occurred over residues 961, 962 and 963, whereas the
next three amino acids (964, 965 and 966) moved most signiﬁ-
cantly when C1015R telomerase was bound to DNA-2 (Fig. 5B). This
difference may arise because the DNA-RNA helix has less base pairs
when DNA-6 is bound to telomerase when compared to DNA-2
(Fig. 5C). Hence, with C1015R telomerase the DNA-6 primer is no
longer base paired to the RNA in the vicinity of residue 962,
resulting in this region of the 957-SLTFNRGFK-965 loop moving
freely without impacting the DNA-RNA helix (Fig. 5C, top left
panel). However, the models show a greater extent of RNA-DNA
binding when telomerase is bound to DNA-2 (Fig. 5C, bottom two
panels). Therefore, the equivalent position for the DNA-2 primer
(G6) is still base-paired to the RNA, restricting the ability of amino
acids 961e963 to move (Fig. 5C, bottom left panel). Thus, to make
room for the larger arginine residue, the more downstream amino
acids (964e966) need to shift. This leads to unfavourable in-
teractions between the DNA-2 primer and the 957-SLTFNRGFK-965
loop (Fig. 5C, bottom left panel) and could explain the reduced
afﬁnity of C1015R telomerase for the DNA-2 primer, which is notseen with the DNA-6 primer.
4. Conclusions
Although the CTE exhibits no evident sequence homology to
retroviral reverse transcriptases, it has long been thought to
constitute the ‘thumb domain’ [27,40,41], a bundle of three a-he-
lices immediately C-terminal to the RT motifs, important in tem-
plate/primer binding and processive nucleotide addition [42].
Analogous to the thumb domain, part of the CTE makes direct
contact with the RNA-DNA hybrid in our model. Our detailed ki-
netic analysis of the C1015R mutation combined with molecular
modelling support the conclusion that C1015R substantially im-
pacts the afﬁnity of telomerase for DNA with different primers due
to the larger arginine residue, resulting in increased movement of a
nearby loop. This provides the ﬁrst direct evidence that motif E-1 of
the CTE is involved in DNA binding afﬁnity.
These data also provide a molecular explanation for the clinical
effect of this mutation. The C1015Rmutationwas found in a 62 year
old woman with therapy-refractory aplastic anaemia [29];
although telomere length measurements were not performed for
this patient, our results indicate that a defect in telomeric DNA
binding caused by the C1015R mutation would likely result in
telomere shortening.
Although the differences between alternate primer off-rates
have been known for some time [26], the molecular basis of
these differences were unknown. Ourmodelling and kinetic studies
now attribute at least part of these differences to different confor-
mational changes in a region of the CTE of hTERT. This leads to a
difference in binding afﬁnities for alternate primers, giving further
support to the analogy between the hTERT CTE and the thumb
domain of retroviral reverse transcriptases.
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